Oncology

Dispensing, communicating, and recording information may look different at each center.

Endometriosis is a systemic disease that can affect multiple parts of the body, not just the pelvis.

Comprising most cases of this rare form of lymphoma, it is essential that pharmacists and treatment providers are aware of the health-related burdens patients with these subtypes consistently face.

The therapy offers new hope in solid tumor treatment with fewer adverse effects.

There are gonadotoxic risks of chemotherapy, radiation, and surgery that are important to discuss with patients.

Multiple P13K inhibitors have showed promise in treating genetically-mutated forms of breast cancer.

The study was conducted on a small subgroup of Japanese patients with myelofibrosis.

The diagnostic test is a companion to vorasidenib, an isocitrate dehydrogenase inhibitor that received FDA approval this past summer.

Non–FDA-approved medications may be accessed for patient care via 3 alternative pathways: expanded access, the Right to Try Act, and off-label use, which are reviewed in this article.

The story of pinksocks and the inspiring movement that they launched.

In a study, RK-33 demonstrated positive effects against the protein DDX3, which is key in the growth of cancer cells and spreading of disease.

Zolbetuximab is the first approved CLDN18.2-targeted treatment for gastric and gastroesophageal junction adenocarcinoma.

The tool can detect cell changes and mutations that drive resistance and relapse.

Awareness of uterine fibroids and uterine fibroid embolization can prevent unnecessary hysterectomies, especially in Black women, who are more likely to have uterine fibroids.

This review discusses the significance of the FDA-approved drug inotuzumab ozogamicin in pediatric patients with acute lymphocytic leukemia (ALL) and relapsed/refractory (R/R) ALL, and the evolving therapeutic options in R/R ALL.

Compared with brentuximab vedotin and chemotherapy, nivolumab and chemotherapy had longer progression-free survival and a better safety profile.

This retrospective cohort study provides preliminary evidence for safe removal of mesna from VAdriaC cycles, as the incidence of hemorrhagic cystitis did not increase in patients with Ewing sarcoma who received cyclophosphamide without prophylactic mesna.

HER2-mutant NSCLC is associated with poor prognosis. Zongertinib and BAY 2927088 are HER2 tyrosine kinase inhibitors that have activity in NSCLC with manageable toxicity profiles.

The KEYNOTE-756 and CheckMate 7FL trials show this combination improves pathological complete response rates in this patient population.

The results indicate the potential use of loncastuximab tesirine as a treatment option for the rare hyperinflammatory condition.

Artificial intelligence holds immense potential to address the rising demand for oncology services and improve patient outcomes by facilitating more effective, efficient, personalized cancer care.

The drug's safety profile included significant rates of nausea, vomiting, and hematologic toxicities like neutropenia and thrombocytopenia. Although promising, brigimadlin requires careful management of adverse effects, including antiemetic and hematologic support.

Although respondents identified some exciting areas of growth, challenges remain, including the complex insurance system and ensuring patient medication adherence.

Shirish Gadgeel, MD, discusses an integrated analysis of the regional TRUST-I study and global TRUST-II study presented at the European Society for Medical Oncology Congress 2024.

Behind The Script is a photo submission campaign designed to feature real pharmacists with candid, HIPAA-compliant photos to celebrate American Pharmacist Month.

The authors of these peer -reviewed papers collectively emphasize the evolving landscape of oncology treatment.

This Women Pharmacists Day, Jolynn Sessions, PharmD, BCOP, FHOPA, discussed the crucial role of women in pharmacy.

Terry Keys highlights the role of language and terminology as barriers for patients receiving cancer care.

The trial met its primary endpoint of event-free survival, furthering treatment options for resected, locally advanced head and neck squamous cell carcinoma.